12,372 trials
Hematopoietic/Lymphoid Cancer
Primary: Behavioral - Stress Level as Measured by the Perceived Stress Scale (PSS) — 23.5; 22.7; 21.6; 22.0 units on a scale — p=0.020
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Primary: Comparison of the Responder Rates Between Two Treatment Groups in the Efficacy Period — 54.2; 20.7 percentage of responders — p=<0.001
Renal Failure
Primary: Composite Endpoint for Efficacy Failure Within 12 Months of Randomization: Death, Graft Failure, Biopsy-proven Acute Rejection or Loss to Follow-up. — 2; 1; 0; 0…
Multiple Myeloma
Primary: Progression Free Survival (PFS) — 88; 71 percentage of participants
Transthyretin Familial Amyloid Polyneuropathy
Primary: Number of Participants With Transthyretin (TTR) Stabilization at Week 8 Compared With Baseline as Measured by a Validated Immunoturbidimetric Assay — 10 Participants
Multiple Sclerosis
Primary: Time to Confirmed Disease Progression (CDP) — NA; NA weeks — p=0.1442
Eczema
Primary: Eczema Area and Severity Index (EASI) on Day 3 - Change From Baseline — -1.783; -0.767 units on a scale — p=<0.0001
Sickle Cell Disease
Primary: Hospital Length of Stay (Hours) — 56; 47 hours — p=0.24
Hepatitis C
Primary: Percentage of Participants With 12 Week Sustained Virologic Response (SVR12) — 81.7; 42.9 Percentage of participants — p=<0.0001
Breast Cancer
Primary: Change in Bone Mineral Density (BMD) Measured by Dual (Energy) X-ray Absorptiometry (DXA) at Lumbar Spine (L2-L4) From Baseline to Month 24 — -0.075; 0.037 Z-score
Severe Hypertension
Primary: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events and Deaths — 20.0; 12.5; 33.3; 48.6 Percentage of participants
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving Remission at Week 16 According to DAS28 — 42.8 percentage of participants — p=0.1648
Hepatitis C, Chronic
Primary: Sustained Virological Response (SVR12) — 70.7; 78.6; 76.7; 72.4 percentage of participants — p=<0.0001
Lymphoma · Infection · Leukemia
Primary: Fungal-free Survival (Percentage of Participants Alive and Free From Proven, Probable, or Presumptive Invasive Fungal Infection) at 180 Days Post-transplant — 74.9; 78.2…
Essential Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 200 mg Versus Olmesartan 20 mg — -20.48; -18.15 mmHg — p=<0.001